[go: up one dir, main page]

MX2018011767A - Composiciones que contienen ácidos tánicos y usos de las mismas. - Google Patents

Composiciones que contienen ácidos tánicos y usos de las mismas.

Info

Publication number
MX2018011767A
MX2018011767A MX2018011767A MX2018011767A MX2018011767A MX 2018011767 A MX2018011767 A MX 2018011767A MX 2018011767 A MX2018011767 A MX 2018011767A MX 2018011767 A MX2018011767 A MX 2018011767A MX 2018011767 A MX2018011767 A MX 2018011767A
Authority
MX
Mexico
Prior art keywords
tanic
acids
same
compositions containing
compositions
Prior art date
Application number
MX2018011767A
Other languages
English (en)
Inventor
Emil Tsai Guochuan
Cheng Wang Ching-
Original Assignee
Syneurx Int Taiwan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syneurx Int Taiwan Corp filed Critical Syneurx Int Taiwan Corp
Publication of MX2018011767A publication Critical patent/MX2018011767A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/49—Fagaceae (Beech family), e.g. oak or chestnut
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C07H1/08—Separation; Purification from natural products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)

Abstract

Composiciones (por ejemplo, composiciones farmaceuticas, composiciones nutraceuticas o composiciones de alimento medicinal) que comprenden acidos tanicos, particularmente acidos tanicos que tienen mas de tres porciones de galoilo, metodos de preparación de los mismos y usos de los mismos para el tratamiento de la obesidad, hiperlipidemia, diabetes o trastornos del sistema nervioso central.
MX2018011767A 2016-03-28 2017-03-28 Composiciones que contienen ácidos tánicos y usos de las mismas. MX2018011767A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662313946P 2016-03-28 2016-03-28
US201762458216P 2017-02-13 2017-02-13
PCT/CN2017/078361 WO2017167168A1 (en) 2016-03-28 2017-03-28 Compositions containing tannic acids and uses thereof

Publications (1)

Publication Number Publication Date
MX2018011767A true MX2018011767A (es) 2019-03-28

Family

ID=59963410

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011767A MX2018011767A (es) 2016-03-28 2017-03-28 Composiciones que contienen ácidos tánicos y usos de las mismas.

Country Status (11)

Country Link
US (4) US10105378B2 (es)
EP (1) EP3436040B1 (es)
JP (2) JP7066627B2 (es)
KR (1) KR102476644B1 (es)
CN (1) CN108348557A (es)
CA (1) CA3018893A1 (es)
HK (1) HK1256040A1 (es)
IL (1) IL261887B2 (es)
MX (1) MX2018011767A (es)
RU (1) RU2715703C1 (es)
WO (1) WO2017167168A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348557A (zh) 2016-03-28 2018-07-31 心悦生医股份有限公司 含有鞣酸的组合物及其用途
JP2021505577A (ja) * 2017-12-07 2021-02-18 シニュークス インターナショナル（タイワン）コーポレイション タンニン酸組成物を調製するための改良された濃縮法
US10927138B2 (en) * 2018-05-29 2021-02-23 Syneurx International (Taiwan) Corp. Inhibitors of D-amino acid oxidase (DAAO) and uses thereof
CN109200272B (zh) * 2018-09-12 2021-11-26 中山大学 一种口服艾塞那肽纳米颗粒制剂及其制备方法和应用
KR102235881B1 (ko) 2018-12-18 2021-04-02 김상희 오배자 추출물 및 프락신을 유효성분으로 포함하는 인지력 개선, 치매 및 과잉행동장애 예방 또는 치료용 조성물
US11154531B2 (en) 2020-02-08 2021-10-26 Syneurx International (Taiwan) Corp. Compounds and pharmaceutical uses thereof
CN116075314A (zh) * 2020-03-20 2023-05-05 新概念医疗有限公司 用于治疗实体瘤和软瘤以及增殖性疾病的组合物和方法
EP4139275A4 (en) * 2020-04-23 2024-07-03 Syneurx International (Taiwan) Corp. Compounds and pharmaceutical uses thereof
WO2021224830A1 (en) 2020-05-05 2021-11-11 Syneurx International (Taiwan) Corp. Salts of neuroceuticals and uses thereof
KR102224178B1 (ko) * 2020-07-24 2021-03-08 재단법인 전남바이오산업진흥원 붉가시나무(Quercus acuta Thunb.) 열매 또는 잎 추출물을 포함하는 인지능력 또는 기억력개선용 조성물
IL300361A (en) * 2020-08-15 2023-04-01 Regeneron Pharma will fall into obesity in patients with variants of nucleic acid compounds encoding the calcitonin receptor
CN112353795A (zh) * 2020-12-14 2021-02-12 中山万汉制药有限公司 奥利司他及其组合物的抗疟疾用途
KR102897404B1 (ko) 2021-10-25 2025-12-16 서울대학교산학협력단 신규한 락토바실러스 플란타럼 d2-3 균주 및 이의 용도
TW202423407A (zh) * 2022-07-26 2024-06-16 心悅生醫股份有限公司 治療流感病毒之組合物及方法
CN116115731A (zh) * 2023-01-20 2023-05-16 安徽泰格生物科技有限公司 一种降血糖的组合物、制剂及其应用
CN119499263B (zh) * 2024-12-10 2026-01-23 阜外华中心血管病医院 五没食子酰葡萄糖在制备抗阿霉素心脏毒性药物中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPH0751507B2 (ja) * 1988-02-23 1995-06-05 株式会社日本ハイポックス タンニン酸の渋味及び苦味低減方法
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5571551A (en) * 1993-05-27 1996-11-05 Kraft Foods, Inc. High molecular weight gallotannins as a stain-inhibiting agent for food dyes
EP0877076B1 (en) 1997-05-09 2003-11-12 Rohm And Haas Company Detergent formulations
KR20000019718A (ko) 1998-09-15 2000-04-15 박호군 탄닌 또는 탄닌 유래 페놀성 화합물을 포함하는 동맥경화증, 고지혈증 및 간질환의 예방 및 치료용 조성물
CA2364484A1 (en) 1999-03-09 2000-09-14 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
CN1276926C (zh) 2002-09-10 2006-09-27 北京富邦博尔生物科技有限公司 一种单宁酸的纯化方法
CN1193763C (zh) * 2003-04-10 2005-03-23 四川倍达尔新技术开发有限公司 红景天总鞣质提取物及其在制备治疗老年性痴呆病药物中的应用
CN1313475C (zh) * 2003-04-22 2007-05-02 上海大学 虎杖提取物虎杖鞣酸在制备降血糖、治疗糖尿病药物中的应用
CN1560077A (zh) 2004-03-05 2005-01-05 山东大学 一种环丙沙星免疫原及其制备方法
US20090118202A1 (en) 2007-10-31 2009-05-07 Texas Tech University Compositions and methods of treating hypertension with tannin complexes
KR20090084159A (ko) * 2008-01-31 2009-08-05 경북대학교 산학협력단 감 추출물 또는 탄닌을 유효성분으로 함유하는면역관련질환 치료용 조성물
US20120052053A1 (en) * 2008-11-14 2012-03-01 Manning-Bog Amy B Compositions and methods for the treatment of altered alpha-synuclein function
CN101618066B (zh) * 2009-08-04 2011-09-28 天津科技大学 核桃青皮总单宁的制备及其应用
WO2011149835A1 (en) * 2010-05-24 2011-12-01 Max International, Llc Compositions and beverages comprising nutrients, vitamins, sugars, cysteine, and/or sugar-cysteine products
JP2012116791A (ja) * 2010-12-01 2012-06-21 Kao Corp オートインデューサー−２阻害剤
CN102127125B (zh) 2011-01-05 2015-10-14 中国林业科学研究院林产化学工业研究所 系列精制单宁酸多元组合化纯化制备工艺及其产品的组合化制备
CN102180917A (zh) * 2011-03-20 2011-09-14 竹山林产化工实业有限公司 一种药用单宁酸的制备方法
CN102250159A (zh) * 2011-04-28 2011-11-23 贵阳单宁科技有限公司 从含单宁的植物原料中提取和制备高纯度单宁酸的方法
CN102743419A (zh) * 2012-05-31 2012-10-24 兰州理工大学 路路通总鞣质提取物的制备方法及其用途
CN108348557A (zh) 2016-03-28 2018-07-31 心悦生医股份有限公司 含有鞣酸的组合物及其用途

Also Published As

Publication number Publication date
EP3436040A1 (en) 2019-02-06
JP2019515891A (ja) 2019-06-13
IL261887B2 (en) 2023-08-01
JP7066627B2 (ja) 2022-05-13
CA3018893A1 (en) 2017-10-05
WO2017167168A1 (en) 2017-10-05
JP2022075675A (ja) 2022-05-18
HK1256040A1 (zh) 2019-09-13
KR20190005157A (ko) 2019-01-15
US20180133237A1 (en) 2018-05-17
IL261887A (en) 2018-10-31
KR102476644B1 (ko) 2022-12-09
US11202791B2 (en) 2021-12-21
EP3436040A4 (en) 2019-12-11
US10265336B2 (en) 2019-04-23
RU2715703C1 (ru) 2020-03-03
US20190201427A1 (en) 2019-07-04
IL261887B1 (en) 2023-04-01
US20180092935A1 (en) 2018-04-05
CN108348557A (zh) 2018-07-31
US20200390791A1 (en) 2020-12-17
US10105378B2 (en) 2018-10-23
EP3436040B1 (en) 2024-11-06

Similar Documents

Publication Publication Date Title
MX2018011767A (es) Composiciones que contienen ácidos tánicos y usos de las mismas.
MX2019000588A (es) Moduladores de la somatostatina y usos de los mismos.
CL2018002758A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue.
BR112017003346A2 (pt) derivados de pirazolopiridina, seus usos, e composição farmacêutica
MX386752B (es) Agonistas del receptor farnesoide x y usos de los mismos.
CR20160485A (es) Compuesto de ciclopropanamina y sus usos
MX390064B (es) Formas cristalinas de mononucleotido de beta-nicotinamida.
BR112017015536A2 (pt) ?métodos de purificação de canabinoides, suas composições e kits?
CL2018002718A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2019002745A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
EP3391888C0 (en) MEDICATION FOR TREATING INFLUENZA CHARACTERIZED BY COMPRISING A COMBINATION OF A CAP-DEPENDENT ENDONUCLEASE INHIBITOR WITH AN ANTI-FLU DRUG
CL2017000782A1 (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación del virus del dengue
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
MX2017011269A (es) Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
CL2019003309A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2019002744A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2016003212A1 (es) Derivados de indolín-2-ona o pirrolo-piridín-2-ona.
CL2019003294A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2018002729A1 (es) Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue.
MX2021003110A (es) Agonistas del receptor x farnesoide y usos de los mismos.
BR112016025876A8 (pt) composição, processos para preparar uma microcápsula e uma forma de dosagem unitária, forma de dosagem unitária, microcápsula, produto, uso de uma composição, e, método para tratar uma condição associada à vitamina k1 ou k2
CY1121880T1 (el) Συνθεση για την οφθαλμικη υγεια
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
BR112017019728A2 (pt) combinações e formulações de dose fixa compreendendo etc1002 e uma ou mais estatinas e método para tratar ou reduzir o risco de doença cardiovascular
DOP2016000161A (es) Ureas asimétricas p- sustituidas y usos médicos de las mismas.